Alexion Pharmaceuticals says a second late-stage study of its anemia drug Soliris demonstrates the pharmaceutical is safe and well tolerated and hit all primary and secondary endpoints. Soliris is being developed as a therapy for PNH, a rare form of anemia that is triggered by a genetic blood disorder suffered by 8,000 to 10,000 patients in North America.
"We continue to target submission of marketing applications for Soliris in PNH during the second half of this year and we look forward to providing a further update this summer regarding our plans with U.S. and European regulatory agenciesm," says Alexion CEO Leonard Bell.
- here's the release from Alexion